Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention.

Turner, Richard M; Fontana, Vanessa; FitzGerald, Richard; Morris, Andrew P; Pirmohamed, Munir

Turner, Richard M; Fontana, Vanessa; FitzGerald, Richard; Morris, Andrew P; Pirmohamed, Munir.

Afiliação

Turner RM; Department of Molecular & Clinical Pharmacology, University of Liverpool, United Kingdom.
Fontana V; Department of Molecular & Clinical Pharmacology, University of Liverpool, United Kingdom.
FitzGerald R; Department of Molecular & Clinical Pharmacology, University of Liverpool, United Kingdom.
Morris AP; Department of Biostatistics, University of Liverpool, United Kingdom.
Pirmohamed M; Department of Molecular & Clinical Pharmacology, University of Liverpool, United Kingdom.

Br J Clin Pharmacol ; 86(1): 62-74, 2020 01.

Article em En | MEDLINE | ID: mdl-31656041

Assuntos

Lactonas; Atorvastatina; Teorema de Bayes; Humanos; Prevenção Secundária

Palavras-chave

drug-drug interactions; loop diuretics; myotoxicity; proton pump inhibitors; smoking, statin; systemic exposure

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lactonas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google